Company: OSRH
Filing Date: 2025-01-31
Form Type: 424B3
Source: 0001213900-25-008874
Chunk: 285

Company: OSR Holdings, Inc.
Filing Date: 2025-01-31
Form: 424B3
Chunk 285
---
2019). “Hepatocellular Carcinoma.” New England Journal of Medicine, 380(15), 1450 -1462 4 https: // www.arizton.com /market -reports /hepatocellular -carcinoma - treatment-market 168 The global HCC treatment market is projected to be valued at $14.18 billion by 2031, from $3.87 billion in 2023 at a CAGR of 17.61%. 5 Metastatic Colorectal Cancer (mCRC) Market The market for global metastatic colorectal cancer is projected to grow at a CAGR of 3.58% for the period 2024 -2031, growing from USD 3.91 billion in 2023 to USD 5.18 billion in 2031. 6The increasing prevalence of colorectal cancer due to low fruit and vegetable intake, excessive alcohol consumption, sedentary lifestyle, smoking, obesity, and high intake of processed meats will create growth opportunities in the market to address the disease. 7 The growth of the metastatic colorectal cancer market is also driven by various factors including increased spending in the healthcare sector generally, rising support from governments globally, growing research and development activities, and increasing efforts towards development of novel diagnostic techniques and enhancement of existing techniques. Increasing awareness, an ageing population, and rising government initiatives to provide affordable treatment and diagnostic solutions in combination with the presence of favorable reimbursement policies also provide expanding growth opportunities to the market. Increasing approval for various diagnostic and treatment solutions by different regulatory bodies including the FDA is further supporting market expansion in this sector. For instance, in 2023, the FDA approved Foundation Medicine’s FoundationOne Liquid CDx as a companion diagnostic for encorafenib combined with cetuximab. The combination therapy received FDA approval for patients with previously treated metastatic colorectal cancer with BRAF V600E alteration. FoundationOne Liquid CDx became the first comprehensive genomic profiling test that was approved by the FDA for detecting BRAF V600E mutations in patients with metastatic colorectal cancer. The companion diagnostic indication provides oncologists with non -invasiveand important genomic testing solutions for patients with metastatic cancers. Osteoarthritis (OA) Market Osteoarthritis is the most common form of arthritis, affecting millions of people worldwide. Osteoarthritis is a progressive degenerative disease of the joints, caused by the breakdown and loss of cartilage in one or more joints. Cartilage is